| 臺大學術典藏 |
2021-02-02T02:21:24Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; MING-SHIANG WU; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.;Kun-Huei Yeh;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.; KUN-HUEI YEH; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:58Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Cheng A.-L.; KUN-HUEI YEH; Lin J.-T.; Hsu C.; Liu M.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.;Shen Y.-C.;Yang C.-H.;Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Liu H.-T.;Li C.-C.;Chen J.-S.;Wu C.-Y.;Cheng A.-L.; Hsu C.; Shen Y.-C.; Yang C.-H.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.;Kun-Huei Yeh;Yang C.-H.;Hsu C.;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H.; Lin C.-C.; KUN-HUEI YEH; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.;Cheng A.-L.;Hsu C.-H.;Lu Y.-S.;Hsu C.;Kun-Huei Yeh;Wu C.-Y.;Huang C.-S.;Yang C.-H.; Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; KUN-HUEI YEH; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Hsu C.; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:38Z |
erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
Hsu C.;Shen Y.-C.;Cheng C.-C.;Cheng A.-L.;Hu F.-C.;Kun-Huei Yeh; Hsu C.; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:37Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen I.C.;Hsu C.;Chen Y.C.;Chien S.F.;Kao H.F.;Chang S.Y.;Hu F.C.;Kun-Huei Yeh; Chen I.C.; Hsu C.; Chen Y.C.; Chien S.F.; Kao H.F.; Chang S.Y.; Hu F.C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.;Li C.-P.;Yen C.-J.;Hsu C.;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Kun-Huei Yeh;Cheng A.-L.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.;Kun-Huei Yeh;Chen L.-T.;Lin C.-W.;Hsu P.-N.;Hsu C.;Wu M.-S.;Tzeng Y.-S.;Tsai H.-J.;Wang H.-P.;Cheng A.-L.; Kuo S.-H.; KUN-HUEI YEH; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:27Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; KUN-HUEI YEH; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.;Guo J.-C.;Hsu C.;Kuo S.-H.;Tien Y.-W.;Cheng A.-L.;Kun-Huei Yeh; Yang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-15T03:47:43Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; HSIU-PO WANG; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:03Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.; Wu Y.-W.; Liu K.-L.; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; HSIU-PO WANG |
| 臺大學術典藏 |
2021-01-15T03:46:45Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; HSIU-PO WANG; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-12T12:49:21Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; Tang J.-L.; Hsu C.; Chen C.-Y.; Tsay W.; SHANG-YI HUANG; Yao M.; Chen Y.-C.; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2021-01-06T03:59:00Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Hsu C.; Lin M.-T.; JIH-LUH TANG; Tien H.-F.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-01-06T03:58:55Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Hsu C.; Wang J.-D.; Hwang J.-S.; Tien H.-F.; Chang S.-M.; Cheng A.-L.; Chen Y.-C.; JIH-LUH TANG |
| 臺大學術典藏 |
2021-01-06T03:58:55Z |
Using standardised measures of health-related quality of life: Critical issues for users and developers
|
Kind P.; Hsu C.; Wang J.-D.; Yao G.; JIH-LUH TANG |
| 臺大學術典藏 |
2021-01-06T03:58:47Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Huang T.-C.; Ko B.-S.; JIH-LUH TANG; Hsu C.; Chen C.-Y.; Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; Shen M.-C.; Wang C.-H.; Tien H.-F. |
| 臺大學術典藏 |
2021-01-05T03:34:41Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Cheng A.-L.; Chen P.-J.; Liu T.-W.; Lin S.-J.; Wang M.-C.; MING YAO; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Hsu C.; Tsou H.-H. |
| 臺大學術典藏 |
2021-01-05T03:34:31Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Taiwan Cooperative Oncology Group; Hsu C.; Cheng A.-L.; Chen P.-J.; Liu T.-W.; Xia N.; Yuan Q.; Lin J.; Lin S.-J.; MING YAO; Chen J.-H.; Chang C.-S.; Tsou H.-H.; Pei S.-N.; Yang H.-C. |
| 臺大學術典藏 |
2021-01-04T12:13:05Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Hsu C.; Lin M.-T.; Tang J.-L.; HWEI-FANG TIEN; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-01-04T12:13:01Z |
Survival-weighted health profile for long-term survivors of acute myelogenous leukemia
|
Tang J.-L.; Chen Y.-C.; Cheng A.-L.; Chang S.-M.; HWEI-FANG TIEN; Hwang J.-S.; Wang J.-D.; Hsu C. |
| 臺大學術典藏 |
2021-01-04T12:12:53Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Chen Y.-C.; Yao M.; Huang S.-Y.; Tsay W.; Chen C.-Y.; Tang J.-L.; Hsu C.; Huang T.-C.; Ko B.-S.; HWEI-FANG TIEN; Shen M.-C.; Wang C.-H. |
| 國家衛生研究院 |
2021-01 |
The case for physical activity as an option in the smoking cessation guidelines: Short and long term benefits beyond expectation from regular exercise
|
Wen, C;Gao, WN;Chen, C;Wai, J;Wen, C;Lu, P;Lee, J;Hsu, C |
| 國立成功大學 |
2021 |
Flow-induced Orientations of Fibers and Their Influences on Warpage and Mechanical Property in Injection Fiber Reinforced Plastic (FRP) Parts
|
Huang, C.-T.;Chu, J.-H.;Fu, W.-W.;Hsu, C.;Hwang, S.-J. |
| 國立成功大學 |
2021 |
Novel Algorithm for Improved Protein Classification Using Graph Similarity
|
Chou, H.;Hsu, C.;Hsu, C.;Yao, K.;Wang, H.;Hsieh, S. |
| 國立成功大學 |
2021 |
WikiContradiction: Detecting Self-Contradiction Articles on Wikipedia
|
Hsu, C.;Li, C.-T.;Saez-Trumper, D.;Hsu, Y.-Z. |
| 國立成功大學 |
2021 |
RetaGNN: Relational temporal attentive graph neural networks for holistic sequential recommendation
|
Hsu, C.;Li, C.-T. |
| 臺大學術典藏 |
2020-12-28T08:14:10Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Yen-Hsuan Ni;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Wang P.-M.; Chao Y.; Chen L.-T.; Hsu C.; Cheng A.-L.; Lin C.-C.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-12-24T07:08:29Z |
Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling
|
Li C.-Q.; Mehendale S.R.; Hsu C.; Dossumbekova A.; Wojcik K.R.; Shao Z.-H.; Qin Y.; Sharp W.W.; WEI-TIEN CHANG; Hamann K.J.; Yuan C.-S.; Vanden Hoek T.L. |
| 臺大學術典藏 |
2020-12-24T06:16:19Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Lee N.-C.; Lai F.; Hsiung H.-C.; Tsai W.-H.; Chiu P.-C.; Chou Y.-Y.; Lee C.-H.; Chen C.-N.; Chang T.-M.; Hsieh W.-S.; Lin S.-P.; Tsai I.-J.; Fan P.-C.; Tsao P.-N.; Chou H.-C.; Chen N.-Q.; Wu E.-T.; Hwu W.-L.; YIN-HSIU CHIEN; Hsu C.; Chen T.-F. |
| 臺大學術典藏 |
2020-12-24T06:16:14Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Lee N.-C.; Lai F.; Lin I.-L.; Kuo C.-W.; Hwu W.-L.; YIN-HSIU CHIEN; Hsu C.; Hung M.-Z. |
| 臺大學術典藏 |
2020-12-24T02:03:45Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Tsao P.-N.; HUNG-CHIEH CHOU; Chen T.-F.; Chen N.-Q.; Hsu C.; Chien Y.-H.; Hwu W.-L.; Wu E.-T.; Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Hung-Chieh Chou;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2020-12-21T08:19:26Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;I-Jung Tsai;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Wu E.-T.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; I-JUNG TSAI; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2020-12-09T01:38:09Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Ni-Chung Lee; Wu E.-T.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; NI-CHUNG LEE |
| 臺大學術典藏 |
2020-12-09T01:38:04Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Kuo C.-W.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Hung M.-Z.;Lin I.-L.;Lai F.;Ni-Chung Lee; Kuo C.-W.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Hung M.-Z.; Lin I.-L.; Lai F.; NI-CHUNG LEE |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:51Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C.;Yang C.-H.;Hsu C.;Pan-Chyr Yang; Chie W.-C.; Yang C.-H.; Hsu C.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:46Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.;Yang C.-H.;Yu C.-J.;Hsu C.;Cheng A.-L.;Pan-Chyr Yang; Kuo S.-H.; Yang C.-H.; Yu C.-J.; Hsu C.; Cheng A.-L.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:37Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Hsu C.;Pan-Chyr Yang; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Hsu C.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:34:49Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Pan-Chyr Yang; Yang C.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:34:36Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; PAN-CHYR YANG; Yang C.-H. |
